Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions

JAMA Cardiol. 2023 Nov 1;8(11):1048-1049. doi: 10.1001/jamacardio.2023.3223.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiotensins*
  • Cost-Benefit Analysis
  • Heart Failure* / drug therapy
  • Humans
  • Neprilysin
  • Stroke Volume
  • Valsartan

Substances

  • Angiotensins
  • Neprilysin
  • Valsartan